• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

DNDi Mourns the Loss of Jacques Pinel

Home > News

DNDi Mourns the Loss of Jacques Pinel

© Ludovic Weyland
17 Aug 2015

The Drugs for Neglected Diseases initiative (DNDi) extends its deepest condolences to the family of Jacques Pinel, who passed away on 14 August 2015.

As a pharmacist, Jacques Pinel was a pillar for Médécins Sans Frontières (MSF) since 1979. He was instrumental in setting up, rationalizing, and implementing all logistics, pharmacy, and medicines policy (including guidelines and emergency kits to name but a few) of MSF and beyond. In 1996, he led the movement of what was to become later the MSF Access Campaign. He later became a key member of the Drugs for Neglected Diseases working group, the precursor to DNDi. Indeed, he was staunch supporter of the creation of DNDi, advocating tirelessly within and outside of MSF. He has been an excellent advisor of the FACT project, which developed two fixed dose combinations of antimalarials. In his advisory role for FACT, Jacques can be accredited with the vital aspect of the patient-friendly packaging of ASAQ.

‘Without Jacques, DNDi would not be what it is today. As a friend and mentor, he will be sorely missed.’
– Bernard Pécoul

© Ludovic Weyland
Jacques Pinel at the MSF General Assembly, June 2011 © Ludovic Weyland

 

 

Read, watch, share

Loading...
Statements
9 Jun 2026

DNDi Statement at the UN Multi-Stakeholder Hearing on Pandemic Prevention, Preparedness, and Response (PPPR)

Press releases
8 Jun 2026

DNDi, GARDP, and MMV join forces to accelerate drug development for patients in greatest need

Statements
19 May 2026

DNDi interventions at the 79th World Health Assembly

Dr Sergio Sosa-Estani
Statements
15 May 2026

DNDi statement on hantavirus outbreak: ‘Investment in pandemic preparedness efforts remains insufficient.’

Statements
13 May 2026

DNDi’s briefing note for 79th World Health Assembly

Close up of legs with sandals on a dry soil
Press releases
12 May 2026

DNDi welcomes GHIT support for global evaluation and registration of fosravuconazole for eumycetoma, in collaboration with Eisai

Press releases
27 Apr 2026

Thailand registers ravidasvir, a simple-to-use and effective antiviral for hepatitis C, expanding treatment options for Thai patients

Stories

Lab lessons that matter: Pharmacy students help bridge the gap in research for neglected diseases

VIEW ALL

Help neglected patients

To date, we have delivered fourteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Youtube X-twitter Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license